Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
复制标题
DOI：
10.1016/s0090-8258(03)00399-8
复制
发表时间：
2003-09-01
影响因子：
4.7
通讯作者：
Belinson, J
中科院分区：
文献类型：
--
作者：
Markman, M;Webster, K;Belinson, J
Objective.有必要找到铂类和紫杉烷难治性卵巢癌的活性药物，作为恶性肿瘤的二线治疗。有限的临床试验经验表明，吉西他滨在这种临床环境中具有活性。我们希望进一步明确吉西他滨在铂类/紫杉烷类难治性疾病妇女中的活性水平。患有卵巢癌或输卵管癌或原发性腹膜癌的患者，其疾病对铂和紫杉烷治疗无效，或有反应但“无治疗间隔（TFI）”小于或等于3个月，或如果TH>3个月，并且他们已经用药物重新治疗但无反应（或经历TFI> 3个月）。
Objective. There is a need to find agents with activity in platinum and taxane refractory ovarian cancer to be employed as second-line therapy in the malignancy. Limited clinical trial experience has suggested that gemcitabine possesses activity in this clinical setting. We wished to further define the level of activity of gemcitabine in women with well-characterized platinum/taxane refractory disease.Methods. Patients with ovarian or fallopian tube cancer or primary carcinoma of the peritoneum, whose disease had either failed to respond to a platinum and taxane treatment, or had responded but the "treatment free interval (TFI)" was less than or equal to3 months, or if the TH was >3 months and they had been retreated with the agents and not responded (or experienced a TFI of